Mosebrook Jeffrey
Known title: SVP, Fin & Princ Acct OfficerCIK: 0001719686
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 937 | $17K | 7/1/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 806 | $8K | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 341 | $3K | 3/10/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 3,345 | $45K | 7/3/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 937 | $12K | 7/1/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 134 | $3K | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 309 | $7K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 5,514 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 111 | $3K | 3/10/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 166 | $4K | 3/10/2025 | View on chart |
| IART | ▼ Sell | Open Market | 1,191 | $26K | 8/19/2024 | View on chart |
| IART | ▲ Buy | Grant | 10,356 | $0 | 7/1/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 223 | $8K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 124 | $4K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 130 | $5K | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,410 | $0 | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 110 | $4K | 3/10/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 166 | $6K | 3/10/2024 | View on chart |
| IART | ▲ Buy | Grant | 808 | $0 | 2/20/2024 | View on chart |
| IART | ▼ Sell | Open Market | 1,177 | $52K | 8/9/2023 | View on chart |
| IART | ▲ Buy | Grant | 12,196 | $0 | 7/3/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 140 | $7K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 64 | $3K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 106 | $6K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 64 | $3K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 121 | $6K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 113 | $6K | 3/11/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 130 | $7K | 3/11/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,832 | $0 | 3/10/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,256 | $0 | 3/10/2023 | View on chart |
| IART | ▲ Buy | Grant | 510 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 231 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 385 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 411 | $0 | 2/13/2023 | View on chart |
| IART | ▼ Sell | Open Market | 279 | $16K | 12/8/2022 | View on chart |
| IART | ▼ Sell | Open Market | 437 | $25K | 8/2/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 44 | $3K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 62 | $4K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 164 | $11K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 232 | $15K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 120 | $8K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 240 | $16K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 144 | $9K | 3/12/2022 | View on chart |
| IART | ▲ Buy | Grant | 1,430 | $0 | 3/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 595 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 843 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 1,398 | $0 | 2/11/2022 | View on chart |
| IART | ▼ Sell | Open Market | 700 | $50K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.